Patients with comorbidities such as CKD had a median serum CRP level of 26.1 mg/L (IQR: 14–37) and a median serum procalcitonin level of 0.31 ng/mL (IQR: 0.1–0.4); DM2 had a median serum CRP level of 29.2 mg/L (IQR: 16–42) and a median serum procalcitonin level of 0.42 ng/mL (IQR: 0.2–0.6); BPH had a median serum CRP level of 26.4 mg/L (IQR: 14–38) and a median serum procalcitonin level of 0.31 ng/mL (IQR: 0.1–0.5); and postmenopausal women had a median serum CRP level of 26.1 mg/L (IQR: 15–36) and a median serum procalcitonin level of 0.37 ng/mL (IQR: 0.1–0.4). This evidence concerns the gene CRP and benign prostatic hyperplasia.